Dexcom and Oura Recreate Ultrahuman Use Case

This is a distribution squeeze, not just a feature overlap. Ultrahuman built a workflow where one app tries to explain how sleep, recovery, meals, and glucose interact, but Dexcom and Oura can now recreate much of that experience from stronger positions at the sensor and ring layers. That matters because the customer can buy the glucose sensor from Dexcom, wear the ring from Oura, and see glucose data inside the Oura app without adding a separate interpretation layer.

• Dexcom did not just sign an integration deal. It put $75M into Oura's 2024 Series D, which tied the sensor supplier to the leading smart ring platform and made metabolic health a shared roadmap rather than a loose partnership.
  1 dexcom 5 sacra
• The product overlap is concrete. Oura's glucose feature pulls Stelo readings into the Oura app, shows glucose alongside ring signals, and supports meal level interpretation. Only glucose data flows in, but that is enough to cover the core consumer use case of seeing how food, sleep, stress, and activity affect blood sugar.
  2 ouraring 3 ouraring 4 dexcom
• Oura also has much more scale to spread this feature across. Estimated revenue reached $1B in 2025, versus Ultrahuman at a $140M annualized revenue run rate as of August 31, 2026. That gives Oura more room to bundle glucose as an add on inside an already large ring and membership base.
  5 sacra 6 sacra

The next step is a more complete upstream bundle. As Dexcom, Abbott, and Oura add coaching, biomarker links, and tighter in app guidance, the market shifts from standalone health intelligence toward bundled sensor stacks. Ultrahuman's path stays strongest where it can turn more data types into better daily recommendations than any single device maker can deliver alone.